Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Insider Sells $584,805.00 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Rating) insider Martin Javier San sold 19,500 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $29.99, for a total value of $584,805.00. Following the completion of the transaction, the insider now owns 91,500 shares in the company, valued at approximately $2,744,085. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Arrowhead Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ:ARWR opened at $29.40 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $26.81 and a 12-month high of $74.77. The company has a market capitalization of $3.11 billion, a PE ratio of -19.86 and a beta of 1.42. The business has a 50 day moving average of $32.85 and a two-hundred day moving average of $36.24. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.16.

Analysts Set New Price Targets

ARWR has been the topic of a number of research analyst reports. Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $72.00 to $64.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 9th. StockNews.com initiated coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. The Goldman Sachs Group boosted their price target on Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, August 8th. Morgan Stanley initiated coverage on Arrowhead Pharmaceuticals in a research note on Friday, September 9th. They set an “equal weight” rating and a $41.00 price target on the stock. Finally, Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research note on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $65.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Arrowhead Pharmaceuticals by 1.2% in the first quarter. BlackRock Inc. now owns 12,155,084 shares of the biotechnology company’s stock valued at $559,014,000 after acquiring an additional 147,021 shares during the period. Vanguard Group Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 10,145,990 shares of the biotechnology company’s stock worth $335,325,000 after buying an additional 76,653 shares during the period. State Street Corp raised its stake in shares of Arrowhead Pharmaceuticals by 19.2% during the 2nd quarter. State Street Corp now owns 5,582,746 shares of the biotechnology company’s stock worth $196,568,000 after buying an additional 900,791 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Arrowhead Pharmaceuticals by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,990,815 shares of the biotechnology company’s stock worth $105,306,000 after buying an additional 69,862 shares during the period. Finally, FMR LLC raised its stake in shares of Arrowhead Pharmaceuticals by 96.1% during the 2nd quarter. FMR LLC now owns 2,742,968 shares of the biotechnology company’s stock worth $96,580,000 after buying an additional 1,344,444 shares during the period. 67.29% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

(Get Rating)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.

Recommended Stories

Insider Buying and Selling by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.